It's an extreme long shot but there's a slim chance that the drug could get the green light from the FDA late next year or perhaps in 2021 for MF.This is a guest contribution by Tyler Laundon, Chief Analyst, Cabot Early Opportunities. Geron, for its part, seems to be pursuing a conditional approval for imetelstat in MF. However, the FDA clearly hasn't shut the door on this high-value indication. The backstory is that imetelstat's mid-stage MF data didn't appear to be strong enough to warrant further development. Having said that, Geron announced earlier this week that the FDA granted Fast Track Designation for imetelstat's other potential indication - intermediate-2 or high-risk myelofibrosis (MF). So, this small-cap stock could take a few years to pay off. The company expects to this all-important study to produce top-line data by mid-2022.
Micro cap stocks 2019 trial#
Imetelstat is currently in a late-stage trial as a treatment for patients with a rare blood disorder known as lower-risk myelodysplastic syndromes. Geron is a cancer specialist with one product in its pipeline: imetelstat. Bottom line: EyePoint could become a red-hot takeover candidate soon if Yutiq and Dexycu live up to expectations sales-wise. EyePoint checks that box in a big way due to its tiny market cap of $178 million and multiproduct eye care portfolio. In short, it's no secret that Bausch is actively hunting for low-cost acquisitions that could rapidly accelerate its turnaround. Bausch Health Companies already has a commercial partnership with EyePoint, but there's a solid rationale for the duo to take this relationship one step further through a full-on buyout. That's an incredibly cheap valuation for a commercial-stage biotech, especially one with two new products on the market.Īnother reason to consider buying this small-cap eye care specialist is for its potential as a buyout candidate. If this line holds, EyePoint's shares would turn out to be trading a less than 2.5 times next year's sales. The big deal is that these two novel eye care products are expected to haul in $72.1 million next year. Specifically, the company launched the chronic non-infectious uveitis treatment Yutiq, as well as the long-lasting postoperative ocular inflammation medicine Dexycu in first quarter of 2019. Its stock warrants a look right now thanks to two major commercial launches earlier this year. EyePoint: A dirt cheap growth stockĮyePoint, as its name spells out, is an emerging eye care specialist. With these points in mind, it might be a good idea to take advantage of this recent weakness in Catalyst's shares.
While nothing is for certain when it comes to clinical trials, there's a better-than-average chance that Firdapse will hit the mark in both of these ongoing studies.
Micro cap stocks 2019 for free#
In a nutshell, Catalyst's decision to price Firdapse on par with other high-priced rare-disease treatments drew a ton of flack from critics because an older medicine - 3,4-DAP - was already being administered for free under a compassionate-use program. The company markets a controversial medicine, Firdapse, indicated for a debilitating neuromusclar disorder known as Lambert-Eaton myasthenic syndrome (LEMS). Catalyst: A rebound is comingĬatalyst is a high-risk, high-reward rare-disease play.
0 kommentar(er)
